[ad_1]
The European drug regulator has announced that it has launched a “review” of the Russian-made coronavirus vaccine, Sputnik V.
Such a decision is considered of key importance towards the approval for the use of this vaccine in the 27 countries of the European Union.
The medicine committee of the European Medicines Agency EMA will review the data from the ongoing studies of this vaccine, until there is sufficient information for its approval. Last month, preliminary results of an advanced study on this vaccine were published in the medical journal The Lancet.
According to published data, the administration of two doses of Sputnik V showed efficacy of 91.6 percent in patients with symptoms of COVID-19. This percentage is close to the effectiveness shown by the other two vaccines, the Pfizer / BioNTech vaccine and the Moderna vaccine.
The “ongoing review” aims to speed up the vaccine approval process, allowing researchers to submit their findings in real time, even before the final study data is ready. So far, the EMA has shed light on green for use with Pfizer / BioNTech, Moderna and AstraZeneca / Oxford vaccines and is expected to decide next week whether or not to approve the Johnson & Johnson vaccine.
top channel
[ad_2]
Source link
